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Abstract
Bipolar disorder prevalence rates vary in the older adult population (defined as age ≥ 65 years), ranging from 1% in com-
munity dwellers to as high as 8–10% in hospital inpatients. Although older agents, including lithium and valproic acid, offer 
significant antimanic efficacy, as supported by a recent randomized controlled trial (RCT), there is growing interest in using 
atypical antipsychotics to treat bipolar disorder in older adults. Newer atypical antipsychotics are of interest based on their 
tolerability and efficacy in the general adult bipolar population. The aim of this review was to systematically examine efficacy 
and tolerability of newer atypical antipsychotics for older adult bipolar disorder (OABD). We conducted a systematic search 
utilizing the MEDLINE, EMBASE, PsycINFO and Cochrane Library electronic databases, with the aim of identifying all 
RCTs comparing newer atypical antipsychotics approved by the US FDA since 2002 (including brexpiprazole, cariprazine, 
lurasidone, iloperidone, asenapine, paliperidone, and aripiprazole) with placebo or another comparator, in the treatment of any 
phase of bipolar disorder (including mania, depression or mixed episodes while used as an acute or maintenance treatment) 
in older adults (> 65 years). We found no RCT data on any of the examined agents. Hence, we changed our search criteria 
to include studies with a lower age cut-off (≥ 55 years), as well as the inclusion of post hoc studies. Two post hoc studies on 
lurasidone suggest its reasonable safety and efficacy profile in the acute and maintenance treatment of OABD; however, there 
are no pharmacoeconomic data on the use of lurasidone in the treatment of OABD. Research data from open-label studies 
on oral asenapine and aripiprazole as add-on therapy suggest that these two agents are adequately tolerated and improved 
symptoms of depression and mania in OABD; hence, there is an urgent need to conduct RCTs on these two agents. Lastly, 
we found no studies for the treatment of OABD with brexpiprazole, cariprazine, iloperidone, or paliperidone.
Key Points 
Lithium and valproic acid remain the gold-standard 
agents for the treatment of bipolar disorder, but they are 
often not well tolerated in the older adult bipolar disor-
der (OABD) population. Newer atypical antipsychotics 
are of interest, based on some efficacy in the general 
adult population.
No randomized controlled data are available on brex-
piprazole, cariprazine, lurasidone, iloperidone, asenap-
ine, or aripiprazole in the treatment of OABD.
Post hoc data suggest lurasidone to be effective and well 
tolerated in OABD.
Randomized controlled studies of newer atypical antip-
sychotics in OABD are urgently required.
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1 Introduction
Evidence suggests the prevalence rates of older adult 
bipolar disorder (OABD) range from 1% in community-
dwelling seniors to as many as 8–10% of geriatric inpatient 
admissions and 17% of geriatric psychiatry emergency vis-
its [1]. With a successfully aging society across the world, 
it is predicted that the population of those above 60 years 
of age will grow 3.5 times more rapidly than the rest of the 
population [2]. With overall improvement in health care, 
patients suffering from bipolar disorder are expected to 
live longer into their late life. This will inevitably lead to 
greater socioeconomic burden on the healthcare system, in 
addition to a greater proportion of individuals with OABD 
presenting to the primary care physician’s office and the 
emergency room, as well as accessing psychiatric services.
Optimal management of bipolar disorder requires both 
acute and maintenance treatment. Current guidelines 
endorse the use of lithium as the prototypical mood sta-
bilizer, and/or the antiepileptic valproic acid, along with 
antipsychotics, as augmenting agents to stabilize mood 
and/or manage agitation in the acute phase, as well as con-
tinuation of some of these agents in the maintenance phase 
[3, 4]. Guidelines also recommend using antidepressants 
in combination with a mood stabilizer for acutely treat-
ing depressive symptoms. While one of these guidelines 
does offer some insight into the management of OABD 
[4], it does not offer a detailed review of the safety and 
efficacy of newer atypical antipsychotics for the treatment 
of OABD.
Current literature guided the first international task 
force on the treatment of late-life bipolar disorder [2] to 
recognize an upcoming epidemic of the older-aged bipolar 
cohort. It also acknowledged the need for a specific treat-
ment approach for this population compared with the adult 
patient with bipolar disorder. The effects of aging per se 
lead to comorbidity with other physical illnesses such as 
cardiovascular disease [5, 6], cerebrovascular disease [7], 
diabetes mellitus, cancer [8], neurological conditions [9], 
and premature mortality from general medical conditions 
[10]. These illnesses require treatment with additional 
medications, which increases the risk of drug interactions 
and adverse effects [11]. Additionally, there are pharma-
cokinetic changes in drug metabolism due to age-related 
reduction in renal clearance, increased risk of drug sensi-
tivity to drugs acting on the central nervous system [12, 
13], and cognitive decline associated with aging [14]. 
Other consensus guidelines recognize these biological fac-
tors and recommend using lower doses of all psychotropics 
in the older-age bipolar patient [3].
The clinical management of OABD continues to be 
largely based on expert consensus and extrapolated from 
studies of the general adult bipolar population [15–18]. 
The first large randomized controlled trial (RCT) on the 
management of acute mania in late-life bipolar disorder 
patients, the GERI-BD study, has recently been published 
[19]. Findings indicated a significant improvement in 
mania scores with lithium compared with valproate in the 
early stages of acute treatment [19]; however, there was 
no significant difference in response rates between the two 
arms [19].
Over the last 15 years, newer atypical antipsychotics, 
such as lurasidone, aripiprazole, asenapine, and caripra-
zine, have been approved by the US FDA for the treatment 
of schizophrenia. Additionally, some of these agents have 
been approved for the treatment of the acute and/or mainte-
nance phase of bipolar illness in the general adult popula-
tion, while some have also been approved for use in the child 
and adolescent bipolar population; however, none of these 
agents are currently approved for the treatment of OABD. 
Theoretically, these agents might offer similar efficacy rates 
compared with the general adult population; however, there 
are no published reviews evaluating the safety or efficacy of 
these agents in the OABD population. Safety concerns of 
these agents include extrapyramidal side effects related to 
dopamine receptor  (D2) blockade (e.g. aripiprazole and brex-
ipiprazole) and potential metabolic side effects. Therefore, 
we aimed to review the safety and efficacy of these newer 
atypical antipsychotics in the management of the OABD. 
Such a review will hopefully better inform the treating cli-
nician, as well as inform the therapeutic potential of these 
agents in this growing and difficult-to-manage population.
We searched all related bipolar disorder terms in the 
Ovid MEDLINE (In-Process and Other Non-Indexed 
Citations, Ovid MEDLINE Daily and Ovid MEDLINE), 
EMBASE (EMBASE Classic and EMBASE), PsycINFO, 
and the Cochrane Library/EBM Reviews electronic data-
bases. Search duration was from database inception to 7 
April 2017. We specifically included the following atypical 
antipsychotics that have been approved by the FDA since 
2002: brexpiprazole, cariprazine, lurasidone, iloperidone, 
asenapine, paliperidone, and aripiprazole. Filters for patients 
aged ≥ 65 years, and RCTs, were added. To identify any cur-
rently ongoing or yet-to-be-published studies, we searched 
the ClinicalTrials.gov registry database, as well as relevant 
psychiatry conferences, for related abstracts over the last 
5 years. Our outcome criteria included change in mood 
scores and proportion of participants achieving a priori cri-
teria of remission or response (e.g. 50% fall in a mania or 
depression rating scale), while secondary outcomes were 
rate of inpatient admission and readmission, change in func-
tion, quality of life, metabolic side effects, and response on 
comorbid psychiatric symptoms such as anxiety.
Using these approaches, we were not able to identify 
any RCTs conducted of these agents in OABD. When 
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subsequently expanding our search to post hoc studies 
assessing data from previous RCTs with a reduced age 
threshold of ≥ 55 years, we identified two post hoc studies 
of lurasidone in the treatment of late-life bipolar disorder. 
Details of the findings of these studies, as well as a descrip-
tion of the pharmacological profile, safety, and efficacy data 
from non-RCT design studies conducted on the other atypi-
cal antipsychotics, are provided below. In addition, we offer 
recommendations on the use of each agent in OABD based 
on such data.
2  Newer Atypical Antipsychotics for Older 
Adult Bipolar Disorder
The mood stabilizers lithium and valproic acid have been the 
mainstay of bipolar management across all age groups for at 
least the last 30 years [20]. It is well known that while lith-
ium has an excellent antimanic, antidepressant and antisui-
cidal effect, it suffers from a very narrow therapeutic index 
[20]. Valproic acid also offers good antimanic effect, but its 
use needs to be regularly monitored for risk of bone marrow 
suppression, hepatotoxicity, hyperammonemia and encepha-
lopathy [21–23]. With advancing age, older adults experi-
ence physiological changes that affect drug pharmacokinet-
ics, including changes in drug distribution, metabolism, and 
excretion [24]. The impact of reduction in total body water 
composition, reduced glomerular filtration rate, and reduced 
hepatic function in older adults further narrows the thera-
peutic index for lithium and valproic acid derivatives [25, 
24]. In addition, older adults tend to be more sensitive to the 
pharmacodynamic effects of all drugs [24, 26]. They also 
tend to have more comorbidities, leading to increased risk of 
drug–drug interactions and drug–disease interactions [11].
Research shows that over the last few years there has been 
an explosion of data on the use of newer atypical antipsy-
chotics in the treatment of bipolar disorder across the age 
span. Besides their efficacy potential, such agents demon-
strate a relatively wider therapeutic index compared with 
lithium or valproate.
2.1  Brexpiprazole
Brexpiprazole is the most recently approved agent, approved 
by the FDA in 2015 for the treatment of schizophrenia and as 
an adjunctive therapy for the treatment of major depressive 
disorder. Like other atypical antipsychotics, brexpiprazole 
is a serotonin-dopamine neurotransmitter modulator [27]. It 
differs from other agents by being a partial agonist at 5-HT1A 
and dopamine  D2 receptors, and is an antagonist a serotonin 
5-HT2A and  adrenergicα1B/2C receptors [27]. In vitro, brex-
piprazole exhibits more  D2 blockade than aripiprazole. It is 
well absorbed, is metabolized by cytochrome P450 (CYP) 
2D6 and CYP3A4, and has a long half-life of 91 h [28]. 
Dosing considerations in the elderly include manufacturer-
recommended dose adjustments for concurrent CYP2D6 or 
3A4 inhibition [28]. In addition, a recommended reduction 
of maximum daily dose from 4 to 3 mg/day is suggested 
in the setting of moderate to severe hepatic dysfunction or 
moderate to severe end-stage renal disease [28]. There were 
no clinically relevant effects on the ECG QT interval, as well 
as minimal changes on serum prolactin levels [28].
There is currently an ongoing trial (NCT03259555) 
assessing the safety and tolerability of brexpiprazole in 
adults with bipolar mania with or without mixed episodes. 
Although the tolerance and safety of this agent has not been 
assessed in adults with bipolar disorder, some of the safety 
aspects have been studied in schizophrenia. Akathisia (5.8%) 
and weight gain (4.7%) were reported in a study of 1256 
patients taking brexpiprazole 6 mg/day compared with pla-
cebo [29]. A newly diagnosed metabolic syndrome was also 
more common compared with placebo (1.2% vs. 0.8%) in 
the short-term, and even higher (3.1%) in longer-term trials 
[29]. Brexpiprazole did not increase the QT interval in the 
trials [29].
We suspect that due to the recent marketing approval of 
brexpiprazole (2015), no data are as yet available regarding 
either the safety or efficacy of this agent in adult or late-life 
bipolar disorder.
While the pharmacological profile of this agent is some-
what unique, including activity on multiple receptor targets 
associated with bipolar disorder and a long half-life, which 
could offer benefits for patients unable to maintain drug 
adherence, the lack of any data on OABD prevents us from 
offering any recommendations of its use in this indication.
2.2  Cariprazine
Cariprazine was also approved in 2015 for the treatment 
of schizophrenia and acute bipolar disorder. Its pharmaco-
logical profile includes being a  D2 partial agonist, similar to 
aripiprazole [30]. It also exhibits a dose-dependent prefer-
ence for occupying  D3 receptors at low doses, with increas-
ing occupation of  D2 receptors as the dose increases [30]. 
In addition, it displays 5-HT1A agonism effects [31, 30]. 
Cariprazine is metabolized by CYP3A4, and the manufac-
turer recommends a 50% dose reduction when coadminis-
tered with a strong CYP3A4 inhibitor such as ketoconazole 
[31, 30]. Furthermore, cariprazine also has a long half-life 
of 48–96 h, while its active metabolite, didesmethyl caripra-
zine, exhibits a half-life of 1–3 weeks [31, 30]. This could 
manifest as a theoretical lack of an acute response and/
or management of agitation in the first few weeks of dose 
titration [31, 30]. It is also recommended that cariprazine 
be started at a lower dose and titrated much slower in the 
elderly due to the risk of orthostatic hypotension [31, 30].
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Cariprazine has been evaluated in adults with bipo-
lar manic or mixed episodes. In a phase II trial, patients 
aged 18–65 years treated with cariprazine 3–12 mg/day 
demonstrated significant improvement in manic symptoms 
using the Young Mania Rating Scale (YMRS), in addition 
to improvements on the Clinical Global Impression (CGI) 
scale [32]. However, patients taking cariprazine experienced 
more instances of akathisia (22%, vs. 6% with placebo) 
and parkinsonism (16% vs. 1%) [32]. In another phase III 
trial of patients aged 18–65 years, the efficacy of low-dose 
(3–6 mg/day) cariprazine was similar to that of high-dose 
cariprazine (6–12 mg/day) [33]. The most common adverse 
effects from these studies include akathisia, parkinsonism, 
and other extrapyramidal symptoms (EPS; 9.6% and 11.2% 
at doses of 3–6 mg and 6–12 mg, respectively), which was 
almost twice the placebo rates (5.6%) [33]. Other common 
adverse effects were constipation (4.8% and 10.7% at doses 
of 3–6 mg and 6–12 mg, respectively) compared with pla-
cebo (2.5%) [32]. Commonly reported adverse effects with 
other atypical antipsychotics, such as weight gain, metabolic 
disturbances, changes on ECG, or elevated prolactin have, to 
date, not been reported with cariprazine [34, 35].
We found both an ongoing trial and a recently completed 
trial assessing the efficacy and tolerability of this agent in 
bipolar depression (NCT02670538, NCT01396447). How-
ever, at the time of this publication, no study results were 
available on the safety and efficacy of cariprazine in OABD. 
and hence there is insufficient data to recommend its use.
2.3  Lurasidone
Lurasidone was approved by the FDA in 2013 for the mon-
otherapy treatment of bipolar depression [36]. It exhibits 
high affinity as well as strong antagonism at  D2, 5-HT2a, 
and 5-HT7 receptors [37]. It also acts as a partial agonist 
at the 5-HT1a receptors. These effects could be of benefit 
in controlling comorbid anxiety [37]. Additionally, it is a 
muscarinic and histaminergic receptor-sparing agent [37], 
which could theoretically offer better tolerability in the 
older aged population due to concerns of cognitive impair-
ment with drugs that block such receptors. Lurasidone is 
primarily metabolized by CYP3A4, and hence it should be 
cautiously coadministered with inducers or inhibitors of 
CYP3A4 [38]. The half-life of lurasidone is 18 h, which 
provides simplicity in once-daily dosing [37, 38]. The drug 
information approved by the FDA suggests starting lurasi-
done at a 40 mg once-daily dose and with slow titration until 
therapeutic response or lack of tolerability, with a maximum 
recommended daily dose of 160 mg [39]. This medication 
should always be consumed with a meal containing at least 
350 calories [39].
A post hoc analysis of an older adult cohort was 
conducted on data from two previous double-blind, 
placebo-controlled studies of lurasidone in the acute 
treatment of adult bipolar depression [40]. This post hoc 
analysis specifically evaluated the efficacy and safety 
of lurasidone in a late-life bipolar depression sample 
(n = 142, age > 55 years). Lurasidone was administered 
at 20–120 mg/day, either as monotherapy or adjunctive 
therapy to either lithium or valproate [40]. In the mono-
therapy group, a mean change at week 6 on the Mont-
gomery–Asberg Depression Rating Scale (MADRS) was 
significantly greater for lurasidone versus placebo (− 14.8 
vs. − 7.1; p = 0.003; effect size 0.83; pooled doses), while 
in the adjunctive therapy group, mean change in MADRS 
scores in the lurasidone group was not significantly differ-
ent from the placebo group (− 13.9 vs. − 11.1; p = 0.398; 
effect size 0.26) [40]. Lurasidone was found to be safe and 
well-tolerated, as evidenced by reasonably low discontinu-
ation rates in both the monotherapy and adjunctive therapy 
studies (< 7.1%) [40]. Additionally, there were minimal 
effects on metabolic laboratory values [40].
The same research group [41] also conducted a post 
hoc analysis of a 6-month open-label extension main-
tenance study of lurasidone in 141 older adults as either 
monotherapy or augmentation therapy. Patients were aged 
55–75 years and had previously completed 6 weeks of a 
double-blind, placebo-controlled treatment with either lur-
asidone 20–120 mg/day monotherapy, or augmentation with 
lithium or valproate [41]. There was minimum increase in 
weight (− 1.0 kg and − 0.4 kg, monotherapy or augmen-
tation, respectively); total cholesterol (− 2.0 mg/dL and 
+ 6.0 md/dL, respectively), triglycerides (+ 2.5 mg/dL and 
+ 6.0 mg/dL, respectively), and HbA1c (0.0% and − 0.1%, 
respectively) [41]. Adverse events occurring at any time in 
the 6-month open-label phase were as follows for the mono-
therapy and adjunctive therapy groups: headache (14.5%, 
10.5%), nasopharyngitis (10.9%, 4.7%), fatigue (9.1%, 
3.5%), insomnia (7.3%, 11.6%), anxiety (7.3%, 7.0%), and 
depression (7.3%, 4.7%). The rates of extrapyramidal side 
effects were reported for akathisia (3.6%, 11.6%), tremor 
(1.8%, 8.1%), and parkinsonism (3.6%, 7.0%) [41]. No clini-
cally meaningful treatment-emergent changes were observed 
in vital signs, ECG parameters, or blood chemistries during 
this time [41]. One male and one female in the monotherapy 
group (and none in the adjunctive therapy group) had a clini-
cally significant increase in prolactin levels [41]. There was 
a significant fall in MADRS scores in both the monotherapy 
(− 6.2) and adjunctive therapy (− 6.7) groups [41].
The above data suggest that lurasidone offers signifi-
cant potential to control depressive symptoms in both the 
acute and maintenance phases of OABD. The lack of seri-
ous adverse events and overall metabolic safety suggests its 
potential role for clinical use in OABD. Data on the pharma-
coeconomic benefits, as well as the long-term effects on car-
diovascular and cerebrovascular parameters, are still needed.
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2.4  Iloperidone
Iloperidone was approved by the FDA in 2009 for the 
treatment of schizophrenia. It has an oral bioavailability 
of 96% and does not require any caloric supplementation, 
unlike lurasidone [42]. The effective dose range has been 
estimated to be between 12 and 24 mg/day [42, 43]. It is 
suggested that the dose be slowly titrated from 1 mg twice 
daily, by doubling the dosage daily to avoid orthostatic 
hypotension [42, 43]. Iloperidone demonstrates high bind-
ing affinity for  D2 and  D3 receptors, α1-adrenergic recep-
tors, and 5-HT2A [42]; however, receptor affinity for  D2 
and 5-HT2A, is low compared with other antipsychotics 
such as lurasidone and asenapine [44]. Iloperidone dem-
onstrates moderate affinity for α2 receptors, and therefore 
may have greater risk of orthostatic hypotension [45, 46]. 
It also shows mild antagonism on 5-HT1A receptors [44]. 
Finally, it exhibits minimal affinity for H1 receptors, thus 
theoretically offering limited sedation and weight gain 
[46]. Iloperidone is extensively metabolized by CYP3A4 
and CYP2D6 [42]. It is therefore recommended that the 
dose be reduced by 50% when coadministered with potent 
inhibitors of these cytochrome systems. There are no 
adjustment recommendations in patients with hepatic or 
renal impairment, however, Sedek et al., noted a doubling 
of half-life in patients with renal impairment compared 
with healthy controls (33.7 vs. 15 h; p < 0.05) [44, 47].
A pooled analysis of three RCTs in schizophrenia noted 
most common adverse events of iloperidone were dizzi-
ness, headache, dry mouth, nausea, and insomnia [48, 49]. 
The rates of discontinuation due to adverse events were 
not statistically different between iloperidone and placebo 
(4.8% for both) and were lower than risperidone (6.2%) 
and haloperidol (7.6%) [48, 49]. Iloperidone-treated 
patients showed significantly low rates of akathisia com-
pared with haloperidol and risperidone [49]. However, 
iloperidone-treated patients demonstrated a significant 
increase in weight of up to 2.1 kg during the 6-week inter-
vention, which was greater than risperidone (+ 1.5 kg) and 
placebo (− 0.3 kg) [49]. In addition, iloperidone-treated 
patients had at least a mild increase in serum glucose [49]. 
There was a linear dose response with the mean increase 
in serum glucose of 7.2 mg/dL [standard deviation (SD) 
1.8–12.6] in the iloperidone 4–8 mg/day group versus 
16.2 mg/dL (SD 3.6–27) in the 20–24 mg/day group [49]. 
The authors also observed a significant linear increase in 
the QTcF interval on their ECG in the iloperidone-treated 
arm (2.9 ms in the 4–8 mg/day dose group vs. 9.1 ms in 
the 20–24 mg/day dose group) [49].
This review did not identify any ongoing or published 
studies of iloperidone for the acute or maintenance phases 
of treatment of either adult or late-life bipolar disorder, and 
hence no clinical recommendations can be offered.
2.5  Asenapine
Asenapine is a newer-generation antipsychotic approved by 
the FDA in 2009 for the treatment of schizophrenia, as well 
as for the management of acute mania or mixed episodes 
associated with bipolar I disorder. Its mechanism of action 
includes being a potent antagonist at dopamine  D2 and 
serotonin 5-HT2A receptors [50]. It also binds to serotonin 
5-HT1A, 5-HT2C, 5-HT6, 5-HT7, histamine  H1 and noradr-
energic α1 receptors [50]; however, it has negligible affinity 
for muscarinic  M1 receptors [50]. It also acts as a partial 
agonist at 5-HT1A receptors [50], which could contribute to 
its additional antianxiety effects. One study showed a low 
incidence of orthostatic hypotension and dizziness despite 
the potent antagonist effects of asenapine at noradrenergic 
α1 receptors [50]. Asenapine is the only antipsychotic drug 
that is available exclusively in sublingual form. Its bioavail-
ability is approximately 35%, which reduces further if taken 
with food or water [51]. Although the terminal half-life is 
approximately 24 h, it is usually administered twice daily 
because the limited surface area in the oral cavity may limit 
the extent of drug absorption for high doses [51]. Asenapine 
is primarily metabolized via glucuronidation by UGT1A4, 
and undergoes oxidative metabolism by CYP1A2 [52]; how-
ever, smoking, which is known to induce CYP1A2, does 
not appear to impact the metabolism of asenapine [52]. As 
it is taken in a sublingual form, it is known to be rapidly 
absorbed, and leads to at least mild to moderate somno-
lence. Such an effect is likely efficacious in the treatment 
of agitation [52], a presenting feature of acute mania. The 
manufacturer does not recommend dosage adjustments for 
older adults, but a clinical trial in patients with schizophre-
nia found that the clearance of asenapine was inversely pro-
portional to age. It was also found that elderly adults (aged 
65–85 years) were exposed to 30% more drug than younger 
adult patients [53]. However, despite the increased exposure, 
short-term asenapine treatment was generally well tolerated 
in elderly patients with psychosis during rapid dosage esca-
lation [54].
We identified a 12-week, prospective, open-label study 
designed to assess the efficacy and tolerability of adjunc-
tive asenapine (n = 15, initiated at 5 mg/day and titrated as 
tolerated) in a non-dementia older adult sample (≥ 60 years 
of age) with suboptimal previous response to other bipolar 
disorder treatments [53]. There was global improvement in 
psychotic, manic, and depressive symptoms (p < 0.05) [53]. 
The most commonly reported adverse effects were gastroin-
testinal discomfort (n = 5, 33%), restlessness (n = 2, 13%), 
tremors (n = 2, 13%), cognitive difficulties (n = 2, 13%), 
and sluggishness (n = 2, 13%) [53]. It is worth mentioning 
that asenapine is known to cause oral hypoesthesia [number 
needed to harm (NNH) 20, 95% confidence interval (CI) 
13–50] [54]. Additionally, cognitively impaired older bipolar 
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patients may not be able to follow the specific instructions 
for its sublingual administration only.
While asenapine has a favorable pharmacological profile, 
which could theoretically be of benefit in treating OABD, 
the lack of any large-scale RCT data, and the reasonably 
poor acceptability rate, limits the support for the clinical 
utility of asenapine in OABD.
2.6  Paliperidone
Paliperidone was approved by the FDA in 2006 for the treat-
ment of schizophrenia, and in 2009 for schizoaffective disor-
der. Its approved dose range for administration is 3–12 mg/
day [55]. It is the 9-hydroxy-risperidone metabolite of ris-
peridone and therefore has a receptor affinity and adverse 
effects profile similar to risperidone [55]. Both risperidone 
and paliperidone have antagonistic activity at the α1, α2,  D2, 
 H1, and 5-HT2A receptors [55]; however, paliperidone has 
been reported to have lower affinity for α2, 5-HT2A, 5-HT1A, 
and 5-HT1D compared with risperidone [55]. Adverse effects 
reported as common to both agents include weight gain, 
insulin resistance, poor blood glucose control and hyper-
prolactinemia [56]. A recent review suggests that all these 
adverse effects are not clinically significant [56], while other 
studies suggest that paliperidone causes a greater increase in 
prolactin compared with its congener risperidone [57, 58]. 
Oral paliperidone is available as an extended-release (ER) 
tablet that is administered once daily, which offers some 
pharmacokinetic advantage over the twice-daily adminis-
tration of risperidone [56]. Per the manufacturer, the shell 
of the ER tablet does not deform as it moves through the 
gastrointestinal tract [59]. It is suspected that this can cause 
problems for patients with pre-existing inflammatory bowel 
disease or pre-existing gastrointestinal tract narrowing, 
although incidence rates for gastrointestinal obstruction 
are unknown [59]. Paliperidone is cleared renally, and the 
manufacturer recommends a dose of 3 mg once daily in 
patients suffering mild renal impairment (creatinine clear-
ance ≥ 50 mL/min to < 80 mL/min) [59]. The dose may be 
increased to a maximum of 6 mg once daily based on clinical 
response and tolerability [59]. For patients with moderate to 
severe renal impairment (creatinine clearance ≥ 10 mL/min 
to < 50 mL/min), the recommended initial dose is 1.5 mg 
once daily, which may be increased to a maximum of 3 mg 
once daily [59]. Similar dose adjustments are suggested for 
the injectable form of paliperidone in patients with renal 
impairment [59].
We found no randomized controlled or open-label trials 
of paliperidone ER in late-life bipolar disorder; however, 
we did find two trials of paliperidone in adult bipolar dis-
order samples. Berwaerts et al., 2011 studied paliperidone 
in a randomized, placebo-controlled design as adjunctive 
therapy to lithium or valproate in the treatment of acute 
mania (age 18–65 years). Eligible patients (n = 300) had a 
mild to moderate manic syndrome, as evidenced by a YMRS 
total score ≥ 20 [60]. Participants were randomly allocated 
(1:1) to continue their mood stabilizer monotherapy or 
receive flexibly administered paliperidone (3–12 mg/day) 
as augmentation treatment for 6 weeks [60]. There was a 
non-significant difference in change scores from baseline 
to endpoint in the YMRS total score for augmentation with 
paliperidone [− 14.3 (SD 10.0)] compared with ongoing 
mood stabilizer monotherapy [− 13.2 (SD 10.9); p = 0.16] 
[60]. The incidence of treatment-emergent adverse events 
was higher with augmentation treatment (70%) than with 
mood stabilizer monotherapy (54%) [60]. Insomnia was the 
most commonly reported adverse event in both treatment 
groups (11%) [60].
In another randomized, placebo-controlled study, oral 
paliperidone ER was used as maintenance treatment in 
patients with bipolar I disorder after resolution of the acute 
manic phase [61]. Study participants included 766 patients 
aged 18–65 years administered flexible-dose paliperidone 
(3–12 mg/day) or olanzapine (5–20 mg/day) during a 3-week 
acute treatment phase before entry into the maintenance 
phase [61]. They found that the median time to recurrence of 
any mood symptoms in the maintenance phase was 558 days 
with paliperidone ER, and 283 days with placebo, while 
there was lack of recurrence of mood symptoms on patients 
taking olanzapine [61]. Overall, the time to recurrence of 
any mood symptoms was significantly longer with paliperi-
done ER than placebo [p = 0.017; hazard ratio (placebo: 
paliperidone ER; unweighted 95% CI): 1.43 (1.03; 1.98)] 
[61]. Such a difference was found to be significant for pre-
venting recurrence of manic symptoms, but interestingly not 
for depressive symptoms [61].
The pharmacological profile of paliperidone ER offers 
some theoretical safety benefit over risperidone in the treat-
ment of bipolar disorder; however, this is not supported by 
similar prevalence rates of adverse events with this agent. 
Additionally, its role in acute and maintenance treatment of 
adult bipolar treatment is weak, as per published RCT data. 
Lastly, there are no ongoing or completed trials of this agent 
in late-life bipolar disorder, and hence it cannot be recom-
mended for routine use in the management of this disorder.
2.7  Aripiprazole
Aripiprazole was approved by the FDA in 2002 for the treat-
ment of schizophrenia, in 2004 for acute manic and mixed 
episodes, and in 2007 as an adjunct for major depressive 
disorder [62]. Aripiprazole is marketed in doses ranging 
from 2 to 30 mg/day, with a recommended starting oral dose 
of 15 mg/day in schizophrenia and acute manic and mixed 
episodes of bipolar [63]. In addition, in July 2017, Abilify 
Maintena, an ER injectable suspension of aripiprazole, was 
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approved by the FDA for maintenance monotherapy treat-
ment of bipolar I disorder in adults [64].
The pharmacology of aripiprazole is somewhat unique in 
being the first atypical antipsychotic with  D2 partial agonist 
activity [63]. It also has partial agonist activity at the  5HT1A 
receptors and antagonist activity at  5HT2A receptors [63]. 
Aripiprazole is well absorbed and administered once daily 
due to its long half-life of 146 h [63]. It is known to undergo 
hepatic metabolism via CYP2D6 and CYP3A4 to its active 
metabolite dehydroaripiprazole [63]. Patients taking a strong 
CYP3A4-inducing medication such as carbamazepine 
should double the oral dose of aripiprazole over 1–2 weeks 
[63]. Patients who are slow CYP2D6 metabolizers, or tak-
ing a CYP2D6 or CYP3A4 inhibitor, may require half the 
usual dose, while patients who are taking concomitant strong 
CYP2D6 and CYP3A4 inhibitors may require one-quarter 
of the usual dose of aripiprazole compared with patients not 
impacted by CYP2D6 or 3A4 activity [63].
In the elderly, it is recommended to start on a lower dose 
and titrate slowly. As a result of partial  D2 agonism, and less 
 D2 blockade, aripiprazole has been found to have a lower 
incidence of EPS compared with some antipsychotics [65]. 
Furthermore, it offers the least risk of hyperprolactinemia 
[65]. Additionally, it seems to have lesser sedative potential 
than other antipsychotics [65]. Lastly, a large comparative 
efficacy and tolerability meta-analysis of 15 antipsychotics 
used in the treatment of schizophrenia showed that aripipra-
zole caused at least a mild grade of weight gain compared 
with other antipsychotics, and caused significant weight 
gain compared with placebo (standardized mean difference 
− 0.17, 95% CI − 0.28 to − 0.05; a negative value suggests 
more weight gain compared with placebo) [65].
The recent Canadian Network for Mood and Anxiety 
Treatments (CANMAT) treatment guidelines indicated that 
aripiprazole monotherapy can be used as first-line therapy 
for the treatment of acute mania, and in maintenance therapy 
of adult bipolar disorder [4]. These guidelines continue to 
recommend that this agent not be used as a monotherapy 
agent in acute depression [4]. Based on the available evi-
dence, these guidelines also suggest a level 4 recommenda-
tion for the use of aripiprazole in the treatment of OABD 
based on a single open-label study. This particular study 
was a 12-week prospective trial of add-on oral aripiprazole 
in 20 adults aged 50 years and older in the acute treatment 
of bipolar disorder [66]. Patients were administered oral 
aripiprazole initiated at doses of 5 mg/day, and the dose 
was increased as tolerated. Participants had a significant 
reduction in their mean depression scores on the Hamil-
ton Depression Scale (HAM-D), from a baseline score of 
13.8 (SD 6.6) to 6.1 (SD 3.71) [p < 0.001] in the 12-week 
period [66]. Additionally, there was an improvement in 
mania symptoms on the YMRS; baseline scores of 8.6 (SD 
5.66) fell to 3.9 (SD 2.05) [p < 0.03] [66]. There were also 
significant improvements in functional status as measured 
by the Global Assessment Scale (GAS; p < 0.001) [66]. 
The mean ± SD daily dose of aripiprazole used in this trial 
was 10.26 mg/day (SD 4.9) [66]. Authors commented that, 
overall, the drug was adequately tolerated in this older adult 
population [66].
In the unpublished literature, we identified a 12-week 
open-label trial of aripiprazole in the treatment of refrac-
tory bipolar depression. This study was initiated in 2004 and 
completed in 2009. Patients were recruited if they were aged 
between 18 and 75 years. No further details are currently 
available in the public domain, likely because the study was 
withdrawn (NCT00223496). Another multicenter clinical 
trial investigated the safety and efficacy of extended admin-
istration of oral aripiprazole in combination with a mood 
stabilizer for the maintenance treatment of patients with 
bipolar disorder experiencing a manic or mixed episode. 
Participants were administered open-label 12, 24, or 30 mg/
day aripiprazole for 154 days. Subjects were also coadmin-
istered a mood stabilizer. Of the 55 recruited patients, three 
were aged ≤ 18 years and the rest were of adult age range 
(18–65 years of age, n = 52). Participants’ mania symptoms 
were monitored using the YMRS and CGI–Bipolar Version 
(CGI-BP) scales. The mean fall on the YMRS was − 18.3 
(SD 12.71), while on the CGI-BP, the mean fall was −2.4 
(SD 1.76) [NCT00606320]. No statistical tests of compari-
son were published.
Aripiprazole has been on the market for the longest 
period of time compared with the rest of the reviewed atypi-
cal antipsychotics. While it offers clinically effective mood 
augmenting response with venlafaxine in the treatment of 
late-life unipolar depression [67], its safety and efficacy has 
not been established in OABD. With the lack of good-qual-
ity RCT data in OABD, this agent cannot be recommended 
for routine use.
3  Conclusions
As the world’s population ages, it is expected that the num-
ber of patients being treated for bipolar disorder in later 
life will increase in both primary care and secondary care 
hospital settings. Given the complex needs of this group of 
patients, newer treatment options are sorely needed. Lith-
ium and valproic acid remain the treatment of choice for 
the management of OABD based on accumulated clinical 
experience and confirmed by recent evidence [19]. Over the 
last 15 years, at least seven new atypical antipsychotics have 
come onto the market for the treatment of schizophrenia; 
however, only a few have gained marketing approval for 
the additional indication of treatment of bipolar disorder. 
Our review of these seven newer atypical antipsychotics 
found no RCT studies of any of these agents in any phase of 
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OABD. On expanding our scope of this review, we included 
two post hoc studies of lurasidone, and found a reasonable 
efficacy profile of this agent in the acute and maintenance 
treatment of this illness, and hence lurasidone can be recom-
mended for routine use. Further cost–benefit analysis of this 
agent remains to be investigated. Initial data from open-label 
studies also shows promise for the use of oral asenapine and 
aripiprazole as adjunctive therapy, but such findings need to 
be confirmed in RCTs. There are no data to support the use 
brexpiprazole, cariprazine, iloperidone, and paliperidone in 
the treatment of OABD. Future studies are sorely needed 
in this area.
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